Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 5/20 | 0.42 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4474051 | 0.84 | DRD4 (0.48) | DRD4KCNJ1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5618649 | 0.84 | DRD4 (0.48) | DRD4KCNJ1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4487605 | 0.84 | DRD4 (0.48) | DRD4KCNJ1ALDH1A1MAPTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5618667 | 0.83 | DRD4 (0.48) | DRD4KCNJ1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL7023395 | 0.79 | DRD4 (0.48) | DRD4KCNJ1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4481896 | 0.79 | DRD4 (0.49) | DRD4KCNJ1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6668238 | 0.77 | DRD4 (0.43) | DRD4ALDH1A1SMN1; SMN2LMNAACHE | |
| SCHEMBL4492306 | 0.74 | KCNJ1 (0.37) | DRD4KCNJ1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6642668 | 0.72 | CCR3 (0.46) | DRD4ALDH1A1LMNA | |
| SCHEMBL27620276 | 0.70 | ALDH1A1 (0.38) | DRD4ALDH1A1SMN1; SMN2GAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622464-B2 | Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases | GLAXO GROUP LIMITED (GB) | 2009-11-24 | — | — | US | disclosed |
| EP-1487828-B1 | MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-11-05 | — | — | EP | disclosed |
| US-20060063765-A1 | Novel compounds | GLAXO GROUP LIMITED (GB) | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063765-A1 | Novel compounds | CCR3, NSUN3, CCR1 | DRD4 1757/4885KCNJ1 2059/4885ALDH1A1 2920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.